

EAACI Allergy School 2025 Biologicals, type 2 inflammation and eosinophil-associated diseases



4 - 6 September



Florence, Italy














Workshops schedule

Saturday, 06 September 2025, 08:20 - 10:30

Note:

Sessions will run simultaneously in rotation across 3 rooms, ensuring that each attendee has the opportunity to attend all sessions. Participants will be divided into 3 groups, identified by colour: Green, Red or Yellow. **Please pick up your group colour at the EAACI Registration desk upon arrival**. Each group has a specific capacity due to safety regulations. Please follow the colour of the group assigned to you and attend sessions accordingly.

Learning objectives: To discuss hot topics in type 2 and eosinophilic-associated diseases informally, with experts in the field. starting from clinical cases

	Green Group	Red Group	Yellow Group
08:20	Room H	Room I	Room L
	Workshop 1: Clinical corner:	Workshop 2: Clinical corner:	Workshop 3: Clinical Corner:
	What drives the direction of treatment choice in asthma and	Safety of anti-T2 biologicals	Diagnostic approach to high blood eosinophil count
	CRSwNP?	Ibon Eguiluz (Malaga, Spain),	
	Stefano Del Giacco (Cagliari,	Alessandra Vultaggio, (Florence, Italy)	Giovanni Martinelli (Bologna, Italy), Thomas Eiwegger (St.
	Italy), Santiago Quirce (Madrid, Spain)	Learning objectives:	Poelten, Austria)
		to evaluate the safety profile of	Learning objectives: case-based
	Learning objectives: to explore the usefulness of	T2 biologicals currently used in adults and children	discussion of the differential diagnosis of hypereosinophilia
	different clinical, laboratory and	dualts and children	ulugilosis oj riypereosiilopililu
	functional biomarkers in the		
	selection of type 2 biologicals		
09:00	Rotation Break for Speakers	Rotation Break for Speakers	Rotation Break for Speakers
09:05	Room H	Room	Room L
	Workshop 2: Clinical corner:	Workshop 3: Clinical Corner:	Workshop 1: Clinical corner:
	Safety of anti-T2 biologicals	Diagnostic approach to high blood eosinophil count	What drives the direction of treatment choice in asthma and
	Ibon Eguiluz (Malaga, Spain),	C: : : : : : : : : : : : : : : : : : :	CRSwNP?
	Alessandra Vultaggio, (Florence, Italy)	Giovanni Martinelli (Bologna, Italy), Thomas Eiwegger (St.	Stefano Del Giacco (Cagliari,
		Poelten, Austria)	Italy), Santiago Quirce (Madrid,
	Learning objectives: to evaluate the safety profile of T2	Lograina chiactivas casa basad	Spain)
	biologicals currently used in adults	Learning objectives: case-based discussion of the differential	Learning objectives:
	and children	diagnosis of hypereosinophilia	to explore the usefulness of different clinical, laboratory and

			functional biomarkers in the selection of type 2 biologicals
09:45	Rotation Break for Speakers	Rotation Break for Speakers	Rotation Break for Speakers
09:50	Room H Workshop 3: Clinical Corner: Diagnostic approach to high blood eosinophil count Giovanni Martinelli (Bologna, Italy), Thomas Eiwegger (St. Poelten, Austria) Learning objectives: case-based discussion of the differential diagnosis of hypereosinophilia	Workshop 1: Clinical corner: What drives the direction of treatment choice in asthma and CRSwNP? Stefano Del Giacco (Cagliari, Italy), Santiago Quirce (Madrid, Spain) Learning objectives: to explore the usefulness of different clinical, laboratory and functional biomarkers in the selection of type 2 biologicals	Room L Workshop 2: Clinical corner: Safety of anti-T2 biologicals Ibon Equiluz (Malaga, Spain), Alessandra Vultaggio, (Florence, Italy) Learning objectives: to evaluate the safety profile of T2 biologicals currently used in adults and children